Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018
August 30, 2018 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications,...
Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study
August 17, 2018 08:50 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon Therapeutics Reports Second Quarter 2018 Financial Results
August 14, 2018 16:25 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon Therapeutics Reports First Quarter 2018 Financial Results
May 14, 2018 07:45 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results
April 16, 2018 16:35 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction
April 16, 2018 16:10 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors
January 08, 2018 07:15 ET
|
Mateon Therapeutics
· CA4P and checkpoint inhibitor combination nearly doubles amount of tumor necrosis SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a...
Mateon Therapeutics to Present at the 2018 Biotech Showcase
January 03, 2018 07:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
December 05, 2017 08:45 ET
|
Mateon Therapeutics
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapyPreliminary data suggest immuno-oncology...
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results
November 14, 2017 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...